Syngen Biotech Co.,Ltd. (TPEX:8279)

Market Cap	3.27B
Revenue (ttm)	2.12B
Net Income (ttm)	279.44M
Shares Out	27.10M
EPS (ttm)	10.29
PE Ratio	11.71
Forward PE	n/a
Dividend	5.00 (4.27%)
Ex-Dividend Date	Jun 26, 2025

Volume	61,270
Average Volume	81,697
Open	116.50
Previous Close	117.00
Day's Range	116.50 - 121.50
52-Week Range	100.00 - 159.00
Beta	0.12
RSI	53.40
Earnings Date	Aug 8, 2025

About R1 RCM

Syngen Biotech Co.,Ltd., together with its subsidiaries, engages in the research, development, manufacturing, and sale of microbial pharmaceutical raw materials, biological pesticides, fertilizers and biochemical nutritional products, and preventive medicines in Taiwan, China, and internationally. The company offers dietary supplements; supplement contract manufacturing services in the form of sachets, liquids, tablets, cup package capsules, jellies, aluminum and glass bottles, and gummies; science-based and bio active pharmaceutical ingredient...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1988
• Employees: 247
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 8279

Financial Performance

In 2024, Syngen Biotech's revenue was 2.01 billion, an increase of 9.60% compared to the previous year's 1.84 billion. Earnings were 240.21 million, a decrease of -12.60%.